Corcept Therapeutics 주식 (NASDAQ: CORT)

에 대한 최신 뉴스 Corcept Therapeutics (NASDAQ:CORT) 주식

CORCEPT THERAPEUTICS INC

Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Pattaya,,Thailand,-,Circa,April,,2023:,Entrance,To,Calvin,Klein

Mid Cap

News

Movers

Trading Ideas

CELH

COOP

CORT

LOAR

PRGS

VRRM

지난주 상위 중형주를 추적하는 S&amp;P400 지수는 9.1% 하락했고, 특히 금요일에만 4.8% 급락했다. 그러나 이러한 매도세 속에도 시장 흐름을 역행하며 상승한 중형주는 다음과 같다.

굿이어·램웨스턴 등 지난주 S&amp;P 400 급락에도 상승한 중형주 9종목 (3월 31일~4월 4일)

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

CORTS Trust for Bellsouth 7.00% CorTS Ctfs due 12/01/2095

CORTELCO SYS PUERTO RICO by Cortelco Systems Puerto Rico Inc.

Cortelco Systems Puerto Rico Inc

Corteva Inc

Cortex

Structures Products Cp 8% CorTS Issued by Peco Energy Cap Tr II Preferred Stock

Corts Trust Peco Energy Capital Trust III

Corcept Therapeutics Incorporated&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) said on Thursday that it presented results from its Phase 2 DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45787876/corcept-presents-results-from-phase-2-study-of-dazucorilant-in-patients-with-amyotrophic-lateral-s" rel="noreferrer noopener">annual meeting</a>.
In December 2024, the company announced DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42447912/corcept-announces-results-from-phase-2-study-of-dazucorilant-in-patients-with-amyotrophic-lateral-" rel="noreferrer noopener">who received a placebo</a>.
Patients who received dazucorilant experienced substantially more gastrointestinal upset at the onset of treatment than those who received a placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44569564/corcept-therapeutics-stock-jumps-on-upbeat-ovarian-cancer-trial-data-analysts-boost-price-forecast" target="_blank" rel="noreferrer noopener">Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast</a>
Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">300 mg of dazucorilant</a>.
The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received a placebo. Overall survival was a secondary endpoint.
Although DAZALS did not meet its primary endpoint, detailed results at the presentation showed patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group.
An exploratory analysis at the one-year mark shows the survival benefit has continued.
Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study.
The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009).
A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study.&nbsp;The extension study is ongoing.
Dazucorilant has demonstrated an acceptable safety profile, with 92% of adverse events being mild to moderate in severity.
The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received a placebo. The most common adverse effect was mild to moderate, dose-related, transient abdominal pain.
On Monday, Corcept Therapeutics shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45725477/corcept-presents-pivotal-clinical-data-in-asco-late-breaker-with-simultaneous-publication-in-the-l" rel="noreferrer noopener">Oncology Annual Meeting</a>.
ROSELLA met its primary endpoint of improved progression-free survival.
Patients who received relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30% reduction in risk of disease progression compared to patients who received nab-paclitaxel monotherapy.
Median PFS-BICR was extended to 6.5 months, compared to 5.5 months in patients who received nab-paclitaxel alone.
Relacorilant plus nab-paclitaxel was well-tolerated, with a comparable safety profile between treatment arms.
Price Action: At the last check on Thursday, CORT stock was down 0.76% to $69.45.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45796533/humana-backs-reforms-to-limit-medicare-advantage-billing-practices">Humana Backs Reforms To Limit Medicare Advantage Billing Practices</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study

<ul>
<li>DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo</li>
<li>DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo</li>
<li>Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only</li>
<li>Corcept seeking guidance from United States and European regulators on optimum path forward</li>
</ul>

Corcept Therapeutics Presented Results From Its DAZALS Study Of Dazucorilant In Patients With ALS At The European Network To Cure ALS 2025 Annual Meeting, DAZALS Did Not Meet Its Primary Endpoint Of Improved Outcome In The Als Functional Rating Scale-revised Compared To Placebo

WIIM

Corcept Therapeutics shares are trading lower. The company reported its Phase 3 ROSELLA trial results.

<ul>
<li>Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection</li>
<li>Addition of relacorilant did not increase side-effects, compared to nab-paclitaxel monotherapy</li>
<li>Results presented in late-breaking podium presentation at ASCO 2025 with simultaneous publication in The Lancet</li>
</ul>
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the ASCO 2025 (American Society of Clinical Oncology) Annual Meeting.
The presentation abstract can be found <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F243880&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=39fc98b20cea82363bf0c1ee891d18a4">here</a> and the presentation slides <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorcept.com%2Frosella-data-asco-2025%2F&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=d027378ea105f9965e68b33374254744">here</a>. The data have been simultaneously published in The Lancet, titled "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252825%252901040-2%2Ffulltext&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=Relacorilant+and+nab-paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer+%28ROSELLA%29%3A+an+open-label%2C+randomised%2C+controlled%2C+phase+3+trial&amp;index=3&amp;md5=9d1728b37a7ce57af0fea2a9f7d8fcd5">Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial</a>."
ROSELLA met its primary endpoint of improved progression-free survival as assessed by blinded independent central review (PFS-BICR). Patients who received relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients who received nab-paclitaxel monotherapy (hazard ratio: 0.70; p-value: 0.0076). Median PFS-BICR was extended to 6.5 months, compared to 5.5 months in patients who received nab-paclitaxel alone. In addition, PFS assessed by investigators was consistent with PFS-BICR, with a hazard ratio of 0.71 (p-value: 0.0030). An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients' lives. Median OS for patients who received relacorilant was 16.0 months, compared to 11.5 months for patients who received nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.0121). These benefits were seen in all clinically relevant subgroups, including those with poor prognoses.
Relacorilant plus nab-paclitaxel was well-tolerated, with a comparable safety profile between treatment arms. The addition of relacorilant did not increase patients' safety burden. In addition, patients treated with relacorilant plus nab-paclitaxel had a lower incidence of ascites (5.3 percent), than did patients who received nab-paclitaxel alone (10.5 percent). The occurrence of abdominal paracenteses during treatment was also lower for patients treated with relacorilant plus nab-paclitaxel (7.4 percent), compared to nab-paclitaxel alone (13.2 percent).

Corcept Therapeutics Reports Phase 3 ROSELLA Trial Results As Relacorilant Plus Nab-Paclitaxel Improves Survival In Platinum-Resistant Ovarian Cancer Without Added Side Effects, Showing 30% Reduced Progression Risk And 31% Lower Death Risk In ASCO 2025 Late-Breaker And Simultaneous Lancet Publication

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an average annual return of 40.21%. Currently, Corcept Therapeutics has a market capitalization of $8.22 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 5 years ago, it would be worth $5,118.73 today based on a price of $77.56 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748618113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 5 years by 23.49% on an annualized basis producing an average annual return of 38.6%. Currently, Corcept Therapeutics has a market capitalization of $7.63 billion. 
Buying $100 In CORT: If an investor had bought $100 of CORT stock 5 years ago, it would be worth $524.96 today based on a price of $71.92 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747059311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years

Corcept Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NYSE">CORT</a>) short percent of float has fallen 25.63% since its last report. The company recently reported that it has 12.29 million shares sold short, which is 16.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Corcept Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746820856_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Corcept Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Corcept Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Corcept Therapeutics's peer group average for short interest as a percentage of float is 2.83%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Corcept Therapeutics?

Ratings for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Corcept Therapeutics, presenting an average target of $122.89, a high estimate of $150.00, and a low estimate of $78.00. Marking an increase of 17.53%, the current average surpasses the previous average price target of $104.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1746536555_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Corcept Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$131.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Corcept Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Corcept Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>About Corcept Therapeutics</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
<h3>Corcept Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 34.33% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 16.71%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.74%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Corcept Therapeutics: Insights From 9 Financial Analysts

Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, HC Wainwright maintained a Buy rating on the stock but lowered its price target from $150 to $145.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and lowers the price target from $150 to $145.

Price Target

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $145

<h3>Gainers</h3>
<ul>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) shares increased by 21.7% to $1.74 during Monday's after-market session. The market value of their outstanding shares is at $63.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 17.73% to $1.66. The market value of their outstanding shares is at $22.8 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) shares moved upwards by 14.45% to $16.31. The market value of their outstanding shares is at $693.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares rose 11.79% to $122.7. The market value of their outstanding shares is at $12.2 billion. The company's, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock increased by 11.76% to $0.19. The market value of their outstanding shares is at $4.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 11.27% to $0.21. The market value of their outstanding shares is at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 22.2% to $0.86 during Monday's after-market session. The company's market cap stands at $5.1 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock declined by 15.0% to $11.85. The company's market cap stands at $280.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.24% to $0.85. The market value of their outstanding shares is at $60.7 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) stock decreased by 8.13% to $30.54. The market value of their outstanding shares is at $932.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 8.12% to $3.01. The market value of their outstanding shares is at $78.3 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 8.05% to $67.99. The company's market cap stands at $7.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTOR

GCTK

HSTM

NBIX

NCNA

OGEN

SIBN

SNTI

SXTC

TCMD

12 Health Care Stocks Moving In Monday's After-Market Session

Corcept Therapeutics shares are trading lower after the company reported a Q1 sales miss.

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) affirms FY2025 sales outlook from $900.00 million-$950.00 million to $900.00 million-$950.00 million vs $905.38 million estimate.

Guidance

Corcept Therapeutics Affirms FY2025 Sales Guidance of $900.00M-$950.00M vs $905.38M Est

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. This is a 32 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $157.21 million which missed the analyst consensus estimate of $177.94 million by 11.65 percent. This is a 7.09 percent increase over sales of $146.81 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Corcept Therapeutics Q1 EPS $0.17 Beats $0.14 Estimate, Sales $157.21M Miss $177.94M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 10 years ago, it would be worth $11,852.89 today based on a price of $71.25 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025.
<ul>
<li>Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer​ (GOG-3073, ENGOT-ov72)</li>
<li>Oral Abstract Session – Gynecologic Cancer</li>
<li>June 2, 2025, 8:00 AM – 11:00 AM CDT</li>
<li>Abstract Number: LBA5507</li>
</ul>
The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG).

Corcept To Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Platinum-Resistant Ovarian Cancer At ASCO 2025

Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
The publication, Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes, can be accessed at: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;index=1&amp;md5=93462c6dd5567a9a85f2e87e65dc5785">https://diabetesjournals.org/care/lookup/doi/10.2337/dc24-2841</a>.
CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes. Part one of the study screened 1,057 patients at 36 sites across the United States. All patients had hemoglobin A1c greater than 7.5 percent, despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. Using a simple, standardized 1-mg dexamethasone suppression test (DST), 24 percent of these patients were found to have hypercortisolism. These findings were first presented at the American Diabetes Association Scientific Sessions in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Fcorcept-announces-presentation-results-prevalence-phase-catalyst&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=June+2024&amp;index=2&amp;md5=12702a0e0a0fa0edd714c70e67cb4916">June 2024</a>.

Corcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 20 years by 7.21% on an annualized basis producing an average annual return of 15.13%. Currently, Corcept Therapeutics has a market capitalization of $7.34 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 20 years ago, it would be worth $16,746.85 today based on a price of $69.59 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744818312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today

Corcept Begins Trial Of Relacorilant Plus Nab-Paclitaxel And Bevacizumab For Patients With Platinum-Resistant Ovarian Cancer

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

HC Wainwright & Co.

Piper Sandler

Canaccord Genuity

Truist Securities

지난주 상위 중형주를 추적하는 S&amp;P 400 지수는 9.1% 하락했고, 특히 금요일에만 4.8% 급락했다. 그러나 이러한 매도세 속에도 시장 흐름을 역행하며 상승한 중형주는 다음과 같다.
<ol>
<li>코어셉트 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) 주가는 36.28% 급등했다. 코어셉트는 백금 내성 난소암 환자를 대상으로 한 릴라코릴란트(relacorilant)와 냅-파클리탁셀(nab-paclitaxel)의 ROSELLA 3상 임상시험이 <a href="https://www.benzinga.com//node/44569564">맹검 독립 중앙 검토(PFS-BICR</a>)로 평가한 무진행 생존율 개선이라는 1차 평가지표를 충족했다고 발표했다.</li>
<li>미스터 쿠퍼 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) 주가는 28.44% 상승했다. 로켓 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>)가 <a href="https://www.benzinga.com//node/44565671" target="_blank" rel="noreferrer noopener">94억 달러 규모의 전량 주식 거래</a>로 미스터 쿠퍼 그룹을 인수할 것이라고 발표했다.</li>
<li>베라 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) 주가는 10.90% 상승했다.</li>
<li>굿이어 타이어 앤 러버 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) 주가는 10.35% 상승했다. 도이치은행이 보유에서 매수로 투자의견을 상향 조정하고 <a href="https://www.benzinga.com/quote/gt/analyst-ratings" target="_blank" rel="noreferrer noopener">13달러 목표주가를 제시했다</a>.</li>
<li>프로그레스 소프트웨어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) 주가는 예상보다 나은 <a href="https://www.benzinga.com//node/44570749" target="_blank" rel="noreferrer noopener">1분기 재무 실적</a>을 보고한 후 9.30% 상승했다.</li>
<li>램웨스턴 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) 주가는 9.24% 상승했다. 예상보다 나은 3분기 재무 실적을 발표하고 <a href="https://www.benzinga.com//node/44629158" target="_blank" rel="noreferrer noopener">2025회계연도 매출 가이던스가 예상치를 상회했다.</a></li>
<li>셀시우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) 주가는 5.62% 상승했다.</li>
<li>로어 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) 주가는 <a href="https://www.benzinga.com//node/44560215" target="_blank" rel="noreferrer noopener">회사가 분기 실적을 발표한 후</a> 5.26% 상승했다.</li>
<li>PVH(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) 주가는 지난 주 4.68% 상승했다. 강력한 <a href="https://www.benzinga.com//node/44572437" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a> 발표와 5억 달러 규모의 가속 주식 매입 프로그램에 대한 계획을 발표했다.</li>
</ol>
사진 출처: Sorbis via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

굿이어·램웨스턴 등 지난주 S&P 400 급락에도 상승한 중형주 9종목 (3월 31일~4월 4일)

Comments

Corcept Therapeutics

뉴스

에 대한 최신 뉴스 Corcept Therapeutics (NASDAQ:CORT) 주식

일요일, 4월 06, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌